Skip to main content

Advertisement

Springer Nature is making SARS-CoV-2 and COVID-19 research free. View research | View latest news | Sign up for updates

Table 1 Summary of randomized clinical studies of moxibustion for ulcerative colitis with parallel design

From: Moxibustion for ulcerative colitis: a systematic review and meta-analysis

First author (Year) [ref] Sample size (M/F)
Duration of disease
Age (range)
Setting*
(author's affiliation)
Experimental intervention Control intervention Response rate§
(basis of assessment)
Wen
(2003) [16]
69 (35/34)
(A) 6 mon-14 yrs
(B) 4 mon-16 yrs
23-69 yrs
n.r.
(TCM hospital)
(A) Moxa [once daily for 12 days (1 session), 3 day intervals between courses, total 6 sessions n = 39]
Indirect
(B) Sulfasalazine (SASP, oral, 1 g × 4/d, for 3 months, n = 30) A(89.8%, 35/39); B(66.8%, 20/30)
P < 0.05
(Physician's assessment)
Wu
(1999) [17]
151 (n.r.)
(A) 6 mon-18 yrs
(B) 4 mon-16 yrs
(C) 4 mon-17 yrs
25-70 yrs
n.r.
(TCM institute and Western hospital)
(A) Moxa I [once daily for 12 days (1 session), 3 day intervals between courses, total 6 sessions n = 65]
(B) Moxa II(same as A, n = 56)
Indirect
(C) Sulfasalazine (SASP only, oral, early: 1 g × 4/d, firmly: 0.5 g × 4/d, for 3 months, n = 30) A(92.3%, 60/65); B(89.3%, 50/56);
C (66.7%, 20/30)
A, C: P < 0.01;
B, C: P < 0.05
(Physician's assessment)
Ding
(2009) [18]
61 (32/29)
(A) 3 mon-20 yrs
(B) 3 mon-17 yrs
19-71 yrs
n.r.
(Western hospital)
(A) Moxa [20 min, once daily for 2 months, n = 30]
Indirect (ginger)
(B) Sulphasalazine (oral, 1 g × 4/d, for 1 month, n = 31) A(100%, 30/30); B(90.3%, 28/31)
P < 0.05
(Physician's assessment, endoscopy)
Wang
(2006) [19]
60 (28/32)
(A) 0.5-12 yrs
(B) 0.6-13 yrs
27-54 yrs
TCM hospital and private clinics
(TCM hospital and private clinics)
(A) Moxa [once daily for 12 days (1 session), 3 day intervals between courses, total 3 sessions n = 30]
Indirect
(B) Sulphasalazine (1.0 g × 4/d) and Metronidazole (0.2 g × 3/d), oral, [once daily for 10 days (1 session), 3 day intervals between courses, total 3 sessions n = 30] A(86.7%, 26/30); B(66.7%, 20/30)
P < 0.05
(Physician's assessment, endoscopy)
Zhou (2003) [20] 66 (31/35)
2-8 yrs
19-50 yrs
n.r.
(TCM hospital)
(A) Moxa [once daily for 10 days (1 session), 3 day intervals between courses, total 3 sessions n = 34]
Indirect (ginger)
(B) Sulfasalazine (SASP, oral, 0.5 g × 4/d), for 30 days, n = 32] plus Prednisone [(oral, 10 mg × 4/d but reduce to 10 mg/d if getting a more stable state) A(97.1%, 33/34); B(71.9%, 23/32)
P < 0.05
(Physician's assessment, endoscopy)
  1. Sulfasalazine: Anti-inflammatory, Metronidazole: Antibiotic, Prednisone: A synthetic anti-inflammatory glucocorticoid derived from cortisone,
  2. SASP: salicylazosulfapyridine, ACTH: Adreno-Cortico Tropin Hormone, ACH: Adreno-Cortical Hormone
  3. *The most of trials didn't describe the place of remision or neing treaed for active disease in the text. Alternatevely, we report the affiliation of the authors in the brackets.
  4. §Trial divided into three or four categories, including (1) recovery, (2) marked improvement, (3) improvement, and (4) no change in terms of symptom and results of endoscopy.